Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
- 4.2k Downloads
Stimulants used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among stimulants are hindered by the absence of direct comparative trials. The goal of this work was to compare the efficacy of methylphenidate and amfetamine formulations through a meta-analysis of double-blind placebo-controlled trials. We analyzed recent published literature on the stimulant therapy of ADHD to describe the variability of drug–placebo effect sizes. A literature search was conducted to identify double-blind, placebo-controlled studies of ADHD in children and adolescents published after 1979. Meta-analysis regression assessed the influence of medication type and study design features on medication effects. Twenty-three trials met criteria and were included in this meta-analysis. These trials studied 11 drugs using 19 different outcome measures of hyperactive, inattentive, or impulsive behavior. We found significant differences between amfetamine and methylphenidate products, even after correcting for study design features that might have confounded the results. Our analyses indicate that effect sizes for amfetamine products are significantly, albeit moderately, greater than those for methylphenidate. We found that most measures of effect from all studies were statistically significant. Our findings suggest that amfetamine products may be moderately more efficacious than methylphenidate products, even after controlling for potentially confounding study design features. This difference in effect size may be due to differences between amfetamine and methylphenidate in the molecular mechanisms involved in facilitating the dopaminergic neurotransmission.
KeywordsADHD Medications Efficacy Effect size Meta-analysis
This work was supported by Shire Development.
Conflict of interest statement
Dr. Stephen V. Faraone is/has been a consultant for, receives/d research support from, is/has been a speaker for, or is/has been on the advisory board for the following pharmaceutical companies: McNeil, Pfizer, Shire, Eli Lilly and Company, and the Novartis Corporation. Dr. Jan K. Buitelaar is/has been a consultant for, receives/d research support from, is/has been a speaker for, or is/has been on the advisory board for the following pharmaceutical companies: Janssen Cilag BV, Eli Lilly and Company, UCB, Shire, Servier, Bristol-Myer Squibb, Organon, and Bioproject.
- 3.Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476–495CrossRefPubMedGoogle Scholar
- 5.Cohen J (1988) Statistical power analysis for the behavioral sciences. Erlbaum, HillsdaleGoogle Scholar
- 7.Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B (2006) Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics 118:e704–e710CrossRefPubMedGoogle Scholar
- 12.Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629–634Google Scholar
- 19.Faraone SV, Biederman J, Spencer TJ, Aleardi M (2006) Comparing the efficacy of medications for ADHD using meta-analysis. Medscape Gen Med E J 8:4Google Scholar
- 26.Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, Mcclellan J, Rue D, Shaw JA, Stock S, Kroeger K (2001) Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 40:1352–1355CrossRefPubMedGoogle Scholar
- 28.Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Academic Press, OrlandoGoogle Scholar
- 30.Huber PJ (1967) The behavior of maximum likelihood estimates under non-standard conditions. Proc Fifth Berkeley Symp Math Stat Probab 1:221–233Google Scholar
- 31.Hunter JE, Schmidt FL (1990) Methods of meta-analysis: correcting error and bias in research findings. Sage, Newbury ParkGoogle Scholar
- 36.Pelham W, Greenslade K, Vodde-Hamilton M, Murphy D, Greenstein J, Gnagy E, Guthrie K, Hoover M, Dahl R (1990) Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86:226–237PubMedGoogle Scholar
- 42.Stata Corporation (2001) Stata user’s guide: release 7.0. Stata Corporation, College StationGoogle Scholar
- 47.Wilens T, Mcburnett K, Bukstein O, Mcgough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper K, Lynch JM (2006) Multisite, controlled trial of OROS® methylphenidate (CONCERTA®) in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 160:82–90CrossRefPubMedGoogle Scholar